LAG3 and neoplasm: Interestingly, melanoma patients treated with anti-PD-1 (nivolumab) and anti-LAG-3 (relatlimab) in the RELATIVITY-047 clinical trial showed enhanced NKG2A expression on circulating, tumour-specific CD8+ T cells compared to pre-treatment.